vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Construction Partners, Inc. (ROAD). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $809.5M, roughly 1.4× Construction Partners, Inc.). Construction Partners, Inc. runs the higher net margin — 2.1% vs -24.1%, a 26.3% gap on every dollar of revenue. On growth, Construction Partners, Inc. posted the faster year-over-year revenue change (44.1% vs 12.2%). Construction Partners, Inc. produced more free cash flow last quarter ($47.1M vs $46.0M). Over the past eight quarters, Construction Partners, Inc.'s revenue compounded faster (47.6% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Alexander Construction Company was a Palm Springs, California, residential development company that built over 2,200 houses in the Coachella Valley of Riverside County, California, between 1955 and 1965.
ELAN vs ROAD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $809.5M |
| Net Profit | $-276.0M | $17.2M |
| Gross Margin | 51.5% | 15.0% |
| Operating Margin | -22.6% | 6.2% |
| Net Margin | -24.1% | 2.1% |
| Revenue YoY | 12.2% | 44.1% |
| Net Profit YoY | -3350.0% | 663.9% |
| EPS (diluted) | $-0.55 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $809.5M | ||
| Q3 25 | $1.1B | $899.8M | ||
| Q2 25 | $1.2B | $779.3M | ||
| Q1 25 | $1.2B | $571.6M | ||
| Q4 24 | $1.0B | $561.6M | ||
| Q3 24 | $1.0B | $538.2M | ||
| Q2 24 | $1.2B | $517.8M | ||
| Q1 24 | $1.2B | $371.4M |
| Q4 25 | $-276.0M | $17.2M | ||
| Q3 25 | $-34.0M | $56.6M | ||
| Q2 25 | $11.0M | $44.0M | ||
| Q1 25 | $67.0M | $4.2M | ||
| Q4 24 | $-8.0M | $-3.1M | ||
| Q3 24 | $364.0M | $29.3M | ||
| Q2 24 | $-50.0M | $30.9M | ||
| Q1 24 | $32.0M | $-1.1M |
| Q4 25 | 51.5% | 15.0% | ||
| Q3 25 | 53.4% | 17.7% | ||
| Q2 25 | 57.5% | 16.9% | ||
| Q1 25 | 57.3% | 12.5% | ||
| Q4 24 | 50.9% | 13.6% | ||
| Q3 24 | 52.2% | 15.6% | ||
| Q2 24 | 58.2% | 16.1% | ||
| Q1 24 | 57.3% | 10.4% |
| Q4 25 | -22.6% | 6.2% | ||
| Q3 25 | -4.4% | 11.2% | ||
| Q2 25 | 2.0% | 10.6% | ||
| Q1 25 | 5.0% | 4.8% | ||
| Q4 24 | -5.0% | 2.5% | ||
| Q3 24 | 54.3% | 8.5% | ||
| Q2 24 | -2.7% | 8.8% | ||
| Q1 24 | 1.0% | 0.8% |
| Q4 25 | -24.1% | 2.1% | ||
| Q3 25 | -3.0% | 6.3% | ||
| Q2 25 | 0.9% | 5.7% | ||
| Q1 25 | 5.6% | 0.7% | ||
| Q4 24 | -0.8% | -0.5% | ||
| Q3 24 | 35.3% | 5.4% | ||
| Q2 24 | -4.2% | 6.0% | ||
| Q1 24 | 2.7% | -0.3% |
| Q4 25 | $-0.55 | $0.31 | ||
| Q3 25 | $-0.07 | $1.03 | ||
| Q2 25 | $0.02 | $0.79 | ||
| Q1 25 | $0.13 | $0.08 | ||
| Q4 24 | $-0.01 | $-0.06 | ||
| Q3 24 | $0.73 | $0.55 | ||
| Q2 24 | $-0.10 | $0.59 | ||
| Q1 24 | $0.06 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $104.1M |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $969.1M |
| Total Assets | $13.4B | $3.4B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $104.1M | ||
| Q3 25 | $505.0M | $156.1M | ||
| Q2 25 | $539.0M | $114.3M | ||
| Q1 25 | $487.0M | $101.9M | ||
| Q4 24 | $468.0M | $132.5M | ||
| Q3 24 | $490.0M | $74.7M | ||
| Q2 24 | $416.0M | $56.3M | ||
| Q1 24 | $345.0M | $48.0M |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | $1.6B | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | $515.0M | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.8B | — |
| Q4 25 | $6.5B | $969.1M | ||
| Q3 25 | $6.7B | $912.0M | ||
| Q2 25 | $6.8B | $853.3M | ||
| Q1 25 | $6.4B | $807.9M | ||
| Q4 24 | $6.1B | $811.1M | ||
| Q3 24 | $6.5B | $573.7M | ||
| Q2 24 | $5.9B | $552.9M | ||
| Q1 24 | $6.1B | $525.0M |
| Q4 25 | $13.4B | $3.4B | ||
| Q3 25 | $13.6B | $3.2B | ||
| Q2 25 | $13.7B | $2.9B | ||
| Q1 25 | $12.9B | $2.8B | ||
| Q4 24 | $12.6B | $2.6B | ||
| Q3 24 | $13.3B | $1.5B | ||
| Q2 24 | $13.8B | $1.4B | ||
| Q1 24 | $14.0B | $1.3B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | 1.78× | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | 0.90× | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $82.6M |
| Free Cash FlowOCF − Capex | $46.0M | $47.1M |
| FCF MarginFCF / Revenue | 4.0% | 5.8% |
| Capex IntensityCapex / Revenue | 5.4% | 4.4% |
| Cash ConversionOCF / Net Profit | — | 4.80× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $186.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $82.6M | ||
| Q3 25 | $219.0M | $112.0M | ||
| Q2 25 | $237.0M | $83.0M | ||
| Q1 25 | $-4.0M | $55.6M | ||
| Q4 24 | $177.0M | $40.7M | ||
| Q3 24 | $162.0M | $95.9M | ||
| Q2 24 | $200.0M | $34.6M | ||
| Q1 24 | $2.0M | $18.2M |
| Q4 25 | $46.0M | $47.1M | ||
| Q3 25 | $127.0M | $78.9M | ||
| Q2 25 | $180.0M | $46.4M | ||
| Q1 25 | $-69.0M | $14.2M | ||
| Q4 24 | $130.0M | $13.8M | ||
| Q3 24 | $120.0M | $78.4M | ||
| Q2 24 | $166.0M | $19.7M | ||
| Q1 24 | $-22.0M | $-10.6M |
| Q4 25 | 4.0% | 5.8% | ||
| Q3 25 | 11.2% | 8.8% | ||
| Q2 25 | 14.5% | 5.9% | ||
| Q1 25 | -5.8% | 2.5% | ||
| Q4 24 | 12.7% | 2.5% | ||
| Q3 24 | 11.7% | 14.6% | ||
| Q2 24 | 14.0% | 3.8% | ||
| Q1 24 | -1.8% | -2.8% |
| Q4 25 | 5.4% | 4.4% | ||
| Q3 25 | 8.1% | 3.7% | ||
| Q2 25 | 4.6% | 4.7% | ||
| Q1 25 | 5.4% | 7.2% | ||
| Q4 24 | 4.6% | 4.8% | ||
| Q3 24 | 4.1% | 3.3% | ||
| Q2 24 | 2.9% | 2.9% | ||
| Q1 24 | 2.0% | 7.7% |
| Q4 25 | — | 4.80× | ||
| Q3 25 | — | 1.98× | ||
| Q2 25 | 21.55× | 1.88× | ||
| Q1 25 | -0.06× | 13.20× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | 3.27× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | 0.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
ROAD
Segment breakdown not available.
